BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 120 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.31 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $3,979,138 | +1144.9% | 376,100 | +1096.6% | 0.03% | +1033.3% |
| Q1 2021 | $319,643 | +741.2% | 31,430 | +66.9% | 0.00% | – |
| Q1 2020 | $38,000 | -96.5% | 18,829 | -94.0% | 0.00% | -100.0% |
| Q4 2019 | $1,087,000 | +274.8% | 315,000 | +587.8% | 0.01% | +300.0% |
| Q4 2016 | $290,000 | +62.9% | 45,800 | +13.1% | 0.00% | +100.0% |
| Q3 2016 | $178,000 | – | 40,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |